Nature Communications

Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial

2025-12-18

Full text

DOI https://doi.org/10.1038/s41467-025-67528-4